Somatogen, Inc.

Baxter Biotech Technology Sarl

Joseph D Levine

Izydor Z Apostol

Julie A Lippincott

Jacqueline F Aitken

Izydor A Apostol

The present invention relates to methods of controlling beta dimer formation in hemoglobin solutions by altering the metal binding site adjacent to the N-terminus of beta globins. The invention further relates to methods of producing stable, intramolecularly crosslinked beta globins by exposure to Ni(II) and oxone.

Methods of controlling beta dimer formation in hemoglobin

This invention relates to proteins with N-terminal modifications in their amino acid sequence that reduce or eliminate the methylation of the N-terminal methionine that occurs when such proteins are produced in bacteria such as E. coli.

Proteins with mutations to decrease N-terminal methylation

Mutated protein having a sequence with a non-proline amino acid replacement for a proline at amino acid position 4. The mutated protein is not methylated on its N-terminus when expressed in bacteria. The mutated protein is a mutation of a methylated protein that is at least partially methylated on its N-terminus when expressed in bacteria.

Growing community of inventors

Louisville, CO, United States of America

Joseph D Levine